Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".
Press Release Apr 25 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received approval from the DCGI to initiate Phase III trials for Zintrodiazine, a new anti-malarial candidate. The trials will focus on patients with uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax. This development is seen as a significant step in addressing the growing resistance to current malaria treatments. The press release emphasizes Zydus's commitment to innovation in healthcare and the importance of combating malaria.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 16 2026
- Press Release Apr 08 2026
- Press Release Mar 21 2026
- Press Release Mar 19 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
Later from Zydus Lifesciences
- Press Release May 06 2026
- Press Release May 19 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
- Press Release May 28 2026
- Zydus Lifesciences Limited Press Release Jul 03 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences